Biotech & Pharma R&D Valuation Model: Price the Science, Not Just the Financials

Stop using standard DCF models for pre-revenue biotech. Accurately calculate risk-adjusted NPV (rNPV), model clinical trial probabilities, and value your pipeline before Phase I even begins.

Try the Live Interactive Demo

Before you dive into the features, test the power of the Biotech Valuation Model yourself. Access our live, fully functional demo, input your clinical trial data, and see exactly how fast you can calculate your rNPV.

Try Live Demo Now

Traditional Valuation Fails When Your Asset is a Molecule

Valuing a biotech startup is fundamentally different from valuing a SaaS company. You have zero revenue, massive cash burn, and your entire company’s value rests on a binary outcome: will this drug pass FDA approval or not?

If you try to use a standard Excel DCF model, you are forced to project year-one revenues that don’t exist. Worse, you ignore the brutal statistical realities of clinical trials. A drug that looks great in the lab might only have a 15% chance of making it to market. If you don’t discount for that risk, your valuation is a fantasy.

It’s time to value your pipeline the way institutional pharma investors do: using rigorous, risk-adjusted mathematics.

What Makes This the Ultimate Biotech Valuation Tool?

Built for biotech founders, pharma analysts, and healthcare VCs who need to translate clinical data into dollar values.

• Risk-Adjusted NPV (rNPV): The industry gold standard. The model automatically discounts future cash flows by the exact probability of success (POS) for each clinical phase, giving you a realistic present value today.
• Phase-Gate Probability Inputs: Independently adjust the likelihood of success for Pre-clinical, Phase I, Phase II, Phase III, and NDA/Approval based on historical data for the specific indication (e.g., Oncology vs. Cardiovascular).
• Timeline & Capex Modeling: Map out the exact duration and cost of each trial phase. See precisely when you will need to raise your next equity round before running out of cash.
• Peak Sales & Patent Cliff Modeling: Input your target addressable market (TAM), expected market share, and drug pricing. Model the revenue ramp-up to peak sales, and factor in the revenue cliff when the patent expires.
• One-Click Investor Pitch Export: Need to defend your pre-money valuation to a VC syndicate? Export a perfectly formatted PDF showing your rNPV, cash runway, and pipeline probability waterfall in one click.

How It Works

1. Define the Asset: Input the disease indication, target patient population, and expected pricing.
2. Set the Probabilities: Enter the historical success rates for each clinical phase for that specific therapeutic area.
3. Calculate rNPV: View your automated risk-adjusted valuation, peak sales projections, and required funding milestones.

Who Is This Tool For?

• Biotech Founders & CEOs: Understand your company’s true worth before walking into a Series A negotiation. Don’t give away too much equity just because you are pre-revenue.
• Healthcare VC Analysts: Quickly audit a biotech startup’s claims. Run your own sensitivity analysis on their trial probabilities to see if their valuation holds up.
• Pharma BD & Licensing Teams: Calculate the maximum bid you should pay for an in-licensed asset or a merger target based on their clinical stage.
• Life Science Consultants: Deliver institutional-grade valuation reports to your clients without spending weeks building complex spreadsheet architectures.

Enterprise-Grade Features, Zero Friction

• 🌙 Dark Mode Included: Easy on the eyes during deep scientific and financial analysis.
• 💾 100% Local & Private (IndexedDB): Your highly confidential clinical data, trial probabilities, and valuation models never leave your browser. No cloud servers.
• 🔬 Smart Formulas: Automatically handles the complex compounding math of sequential phase probabilities without broken Excel links.
• ⚡ Instant Calculations: Change the Phase II success probability from 40% to 25% and watch the entire rNPV and funding requirements update in milliseconds.

Frequently Asked Questions

What is rNPV and why can’t I just use regular NPV?

Regular NPV assumes a 100% chance of success. In biotech, if a drug has a 10% chance of reaching the market, a regular NPV will drastically overvalue it. rNPV multiplies the future cash flows by that 10% probability, giving you a realistic, risk-adjusted valuation that investors actually trust.

Where do I get the “Probability of Success” numbers?

These are widely published in industry bio-pharma reports (such as those by BIO, Informa Pharma Intelligence, or DiMasi). The model allows you to input these historical benchmark numbers for the specific disease indication you are modeling.

Can I model a company with multiple drugs in its pipeline?

Yes. You can save multiple scenarios (e.g., “Lead Asset”, “Pre-Clinical Asset”) using the local database and simply add the individual rNPVs together to get the total enterprise value of the company.

Is my clinical data secure?

Absolutely. This is a standalone HTML application. It does not send, store, or transmit your confidential trial data or valuations to any external server. Your data stays entirely on your local machine.